Explore the Parkinson's Virtual Biotech

We carefully select the projects with the greatest potential to improve life for people with Parkinson’s. We invest in rapidly testing and developing them.

We act as investors, with the experts and resources to actively monitor and manage each project. We understand the drug development business and are driven by results. But because it’s driven by people with Parkinson’s, not by profits, we’ll invest where others won’t.

Unlike a traditional biotech, our agile approach means that none of our funding is tied up in bricks or people. We have no large teams of scientists or expensive labs to run.

Instead, we partner with institutions and pharmaceutical companies that already have the expertise, tools and infrastructure. We’re not bound by location, or limited to backing research we’ve already funded. We invest in the best ideas and work with the top experts, wherever they are.

Collaboration on a global scale

The Virtual Biotech is made up of:

• over 60 funders, research organisations, universities, biotech companies, trial centres, and charities, from France to Finland, China to Canada
• a long term, multi-million dollar strategic partnership with the Parkinson’s Foundation
• over 400 dedicated people stepping up to take part in pioneering clinical trials
• thousands of generous supporters uniting to find a cure.

Everyone can play a part in the search for a cure for Parkinson's. From funding to volunteering, the more people who get involved, the faster we'll get there.